BRIEF published on 10/01/2026 at 10:05, 1 month 8 days ago IOmx Therapeutics nomme Rüdiger Wolff au poste de directeur financier Directeur Financier Immuno-oncologie Leadership Financier IOmx Thérapeutique Rüdiger Wolff
BRIEF published on 10/01/2026 at 10:05, 1 month 8 days ago IOmx Therapeutics Appoints Rüdiger Wolff as CFO Chief Financial Officer Immuno-oncology IOmx Therapeutics Finance Leadership Rüdiger Wolff
PRESS RELEASE published on 10/01/2026 at 10:00, 1 month 8 days ago iOmx Therapeutics Appoints Rüdiger Wolff as Chief Financial Officer iOmx Therapeutics appoints Rüdiger Wolff as Chief Financial Officer, bringing extensive experience in life sciences and technology finance leadership roles Chief Financial Officer Life Sciences Finance IOmx Therapeutics Rüdiger Wolff
BRIEF published on 04/15/2025 at 10:05, 1 year 6 months ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
BRIEF published on 04/15/2025 at 10:05, 1 year 6 months ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
PRESS RELEASE published on 04/15/2025 at 10:00, 1 year 6 months ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year 10 months ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year 10 months ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year 10 months ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 2 years 2 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
Published on 11/09/2026 at 15:00, 1 hour 4 minutes ago Shelfietech Launched New Retail Software Platform
Published on 11/09/2026 at 14:30, 1 hour 34 minutes ago Boron One Applies for New Exploration Licence
Published on 11/09/2026 at 14:15, 1 hour 49 minutes ago Jericho Energy Ventures to Participate in Cantor Convergence 4th Annual Crypto and AI Infrastructure Conference
Published on 11/09/2026 at 14:00, 2 hours 4 minutes ago Tectonic Metals Adds Mine Development and Alaska Native Partnership Leaders Ahead of 2027 Mineral Resource Estimate and Preliminary Economic Assessment
Published on 11/09/2026 at 15:25, 39 minutes ago EcoGraf Appoints Volkmar Klein as Strategic Advisor to the Board
Published on 11/09/2026 at 15:05, 59 minutes ago DIVEROID's WatchDive Turns Everyday Smartwatches into Dive Computers, Launching on Kickstarter in December
Published on 11/09/2026 at 15:05, 59 minutes ago Harley-Davidson Selects Horizon Global as Growth Partner
Published on 11/09/2026 at 15:00, 1 hour 4 minutes ago PhotonPay Strengthens North American Regulatory Footprint with Canada's RPAA Registration
Published on 11/09/2026 at 14:55, 1 hour 9 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 11/09/2026 at 14:31, 1 hour 33 minutes ago 261109 BENETEAU Transactions sur actions propres
Published on 11/09/2026 at 10:32, 5 hours 32 minutes ago Disclosure of shares outstanding and voting rights - 09.11.2026
Published on 11/09/2026 at 10:32, 5 hours 32 minutes ago Déclaration nombre d'actions et droits de vote - 09.11.2026
Published on 11/09/2026 at 07:00, 9 hours 4 minutes ago bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 9 hours 4 minutes ago BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA
